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When dealing with survival data for a potentially curable cancer,
population-based cancer registries provide information that can be
used to evaluate the performance of health services. For rectal
cancers, Eurocare study results have shown important differences
between European countries (Coebergh, 1995). Variations in
therapy, which have recently been highlighted among countries,
may contribute to these inequalities (Gatta et al, 1996). Stage at
diagnosis is another important determinant in survival.
Nevertheless, it is not routinely collected by all registries and we
are faced with specific problems of standardization, thus stage
at diagnosis cannot as yet be studied on a European scale.
Because the available data on rectal cancer stage were very
accurate and covered a long period of time in the three European
population-based registries (Geneva, Switzerland; Côte d’Or,
France; Mallorca, Spain), it was possible to create a common
classification consistent with TNM staging (Sobin et al, 1997).
The aim of this study was to compare relative survival after rectal
cancer in those three European areas while assessing the effect of
stage at diagnosis.
PATIENTS AND METHODS
The population registries included in the study were the general
Cancer Registry of Geneva (GCR) Switzerland, and the digestive
tract Cancer Registries of Côte d’Or (COCR) France and Mallorca
(MCR) Spain. The populations covered by the registry were
similar in size (for 1985, 371 400 inhabitants in the canton of
Geneva, 473 700 in Côte d’Or and 550 800 in Mallorca). During
the study period, which extended from 1982 (when registration
began in Mallorca) to 1987, 1456 incident cases of rectal cancers
(within 15 cm from the anal verge, ICD-O 1540–1548) were
registered in the three populations. The world age-standardized
incidence rates in males ranged from 12.4 in Mallorca to 15.6 per
100 000 in Côte d’Or, and in females from 7.0 in Mallorca to
9.1 per 100 000 in the canton of Geneva.
The proportion of cases notified by death certificate alone
(DCO) ranged from 0% in the COCR to 6% in the MCR, and the
proportion of histologically verified cases from 96% in the MCR
(after excluding DCO cases) to 98% in the COCR.
The study was restricted to 1148 patients under 80 years of age,
because, past that age, there were disparities between the registries
in the ability both to diagnose and to register cancer cases
(Monnet et al, 1998). Patients with anal cancer (ICD-9 1543:
58 patients), rectal lymphoma or sarcoma (14 patients), DCO
cases (22 patients) and cases discovered at autopsy (eight patients)
were not included.
Studied variables
The three registries routinely collected detailed clinical data, such
as tumour extension and type of treatment, from hospital records,
operative reports and pathology reports. As the staging procedures
used at the time in each registry were different, we created a
classification algorithm taking into account the primary treat-
ment received by the patients. Patients whose data on primary
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Correspondence to: E Monnettreatment were missing were excluded from the stage classifica-
tion (GCR 16 patients COCR five patients). Primary treatment was
recorded by three registries as follows:
1. surgery for cure (macroscopic resection of all tumoural tissue
with no microscopic evidence of proximal and distal margins
involvement)
2. palliative surgery (palliative resection, bypass or colostomy)
3. no surgery.
If a patient had surgery for cure, he was classified according to
pathology report data in one of the four following classes of the
TNM classification: stage I (T1–T2, N0, M0), stage II (T3–T4,
N0, M0), stage III (N1–2, M0) or resected stage IV (M1, if metas-
tases were completely removed surgically). Patients with surgery
for cure, whose histological results were not available, were classi-
fied as stage unknown. In the absence of surgery for cure, patients
were classified as not resected stage IV if a visceral metastasis was
diagnosed (M1), loco-regional in case of palliative surgery without
visceral metastasis (T4, NX, M0), or undetermined in both cases
of no surgery and no detected metastasis (TX, NX, M0).
Statistical analysis
The characteristics of the patients and the distribution of primary
treatment and tumour stage at diagnosis were compared between
registries with the c2 test. Survival was studied for the first 5 years
after the date of diagnostic confirmation. Follow-up data were
actively collected in the three registries by reviewing death
certificates and through contact with hospitals and patients’
physicians. The closing date to determine living or dead status was
31 December 1992. On this date, vital status was available for
99% of the patients in the COCR and 95% of the patients in the
MCR. For the GCR, the statistical analysis was restricted to Swiss
national patients (vital status available for 98% of the patients)
because of the high rate of loss to follow-up for foreigners in the
Geneva canton (Raymond et al, 1995). Foreigners represented
41 patients among the GCR cases. We computed relative survival
rates (Hakulinen, 1982) by using the population life tables
established for the Eurocare study corresponding exactly to the
geographical area of the registries (Micheli et al, 1995). Relative
survival provides an estimate of patients’ survival which is
corrected for the effect of the causes of death independent of rectal
cancer itself. It is defined by the ratio of the observed survival of
cancer patients to the survival of an age, sex, geographic area and
period matched cohort estimated from population life tables. We
compared 5-year relative survival rates according to age at diag-
nosis (categorized into three groups: under 50 years, 50–64 years,
65–79 years), sex, registry and tumour stage at diagnosis by using
the maximum likelihood ratio test (Hakulinen et al, 1987a). Then
we used a multiple regression model (Hakulinen et al, 1987b) to
evaluate simultaneously the effects of different prognostic factors
on relative survival. In this model, patient mortality hazard is set
as an addition to the expected mortality for demographically
similar individuals in general population and to the disease-related
mortality hazard which represents an excess death risk. For this
latter, a proportional hazards model for prognostic covariates is
assumed. In this analysis, the ‘follow-up’ period was divided into
five intervals of 1 year each, and the model was fitted with a
forward selection of variables. The significance of covariates was
tested on the change in deviance. Interaction terms between
significant covariates were systematically tested, as were
interactions between years of follow-up and prognostic factors in
order to study the proportionality of hazards within the time
period.
Analyses were performed on IBM compatible microcomputer
with the BMDP software (University of California Press, Los
Angeles, CA, USA) and the Hakulinen et al programme
(Hakulinen et al, 1985) using a Glim macro (Baker et al, 1978).
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Table 1 Rectal cancer cases in each registry by age, sex, primary treatment and stage at diagnosis
Registry n (%)
Geneva Côte d’Or Mallorca Pa
Age (years)
<50 15 (7) 24 (6) 27 (6) 0.97
50–64 66 (31) 128 (33) 137 (34)
65–79 131 (62) 234 (61) 243 (60)
Sex
Male 106 (50) 260 (67) 248 (61) 10–4
Female 106 (50) 126 (33) 159 (39)
Primary treatment
Surgery for cure 152 (72) 287 (74) 297 (73) 0.29
Palliative surgery 36 (17) 60 (16) 80 (20)
No surgery 24 (11) 39 (10) 30 (7)
Stageb
I (T1–T2 N0 M0) 61 (29) 81 (21) 66 (16) <10–4
II (T3–T4 N0 M0) 47 (22) 110 (29) 102 (25)
III (N1–N2 M0) 38 (18) 93 (24) 101 (25)
IV (M1) resected 5 (2) 2 (1) 12 (3)
Loco-regional (T4–Nx M0) 9 (4) 11 (3) 29 (7)
Undertermined (Tx Nx M0) 9 (4) 23 (6) 13 (3)
IV (M1) not resected 42 (20) 60 (16) 68 (17)
Unknownc 1 (0) 1 (0) 16 (4)
aPearson c2; bfive patients from Côte d’Or exclusively treated by contact radiotherapy were excluded from stage
classification; cpatients with surgery for cure and unknown histological results.For all statistical tests, P-values less than or equal to 0.05 were
regarded as significant.
RESULTS
Neither age distribution nor primary treatment were significantly
different between the registries (Table 1). The proportion of
patients resected for cure was similar in the three registries (GCR
72%, COCR 74%, MCR 73%). On the other hand, there was a
significant difference between the registries in sex ratio and distri-
bution of tumour stage at diagnosis. In the GCR, 61 patients (29%)
were diagnosed in the TNM stage I, versus 81 (21%) in the COCR
and 66 (16%) in the MCR (P < 10–4).
Relative survival rates for each class of the studied variables are
presented in Table 2. In univariate analysis, age and sex did not
have a significant effect on survival, unlike stage at diagnosis
which had an important prognostic effect. Relative survival rates
varied according to registries: survival was lower in the MCR
(35% at 5 years) than in the other two registries (respectively 48%
in the GCR and 47% in the COCR P = 0.01). Five-year relative
survival rates, by stage and site in the three registries, are
presented in Table 3. Differences in survival rates between
registries were slight for stages II, III and IV. On the other hand,
there were greater differences for stage I.
The successive steps to fit the data, when using multiple regres-
sion model for relative survival, are presented in Table 4. After
including the ‘follow-up’ effect, stage was the only variable which
significantly improved the fit of the model. Age, sex and registry
had no significant effect. The relative risk estimates for covariates
with their 95% confidence intervals (CIs) are shown in Table 5.
Stage at diagnosis had a strong effect on the excess death risk
which markedly increased with advancing cancer extension. While
adjusting on stage, age and sex, the excess death risk in the MCR
remained higher than in the other two registries but the difference
was no longer significant.
There was a significant interaction between years of follow-up
and stage (Table 4), showing that hazards were not proportional
across stage classes for the 5 years of follow-up. For undetermined
and metastases stage patients, the relative excess death risks were
3.7 as high for the first 2 years of follow-up as for the subsequent
years (95% CI 1.9–7.3). For stage III patients, it was twice as high
for the second year as for the other years of follow-up (95% CI
1.3–3.2).
DISCUSSION
Our results confirm the existence of a survival difference among
European countries for rectal cancer (Coebergh, 1995), while
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Table 2 Crude and relative survival by age, sex, stage and registry
Survival rates (s.d.)
One year Two years Five years
Crude Relative Crude Relative Crude Relative P a
Age (years)
<50 0.68 0.68 0.53 0.53 0.32 0.33 0.89
(0.06) (0.06) (0.06) (0.06) (0.06) (0.06)
50–64 0.77 0.77 0.64 0.66 0.43 0.46
(0.02) (0.02) (0.03) (0.03) (0.03) (0.03)
65–79 0.70 0.73 0.55 0.60 0.33 0.41
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
Sex
Male 0.72 0.74 0.57 0.62 0.34 0.42 0.97
(0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
Female 0.73 0.74 0.59 0.62 0.38 0.43
(0.02) (0.02) (0.02) (0.02) (0.02) (0.03)
Stageb
I (T1–T2 N0 M0) 0.91 0.94 0.86 0.91 0.67 0.79 <10–4
(0.02) (0.02) (0.02) (0.03) (0.03) (0.04)
II (T3–T4 N0 M0) 0.91 0.93 0.82 0.88 0.53 0.63
(0.02) (0.02) (0.02) (0.03) (0.03) (0.04)
III (N1–N2 M0) 0.81 0.83 0.57 0.61 0.25 0.28
(0.03) (0.03) (0.03) (0.03) (0.03) (0.03)
Loco-regional (T4 Nx M0) 0.39 0.40 0.24 0.26 0.04 0.05
(0.07) (0.07) (0.07) (0.07) (0.03) (0.03)
Undetermined (Tx Nx M0) 0.47 0.48 0.28 0.30 0.16 0.20
(0.08) (0.07) (0.07) (0.07) (0.06) (0.07)
IV (M1) 0.27 0.28 0.07 0.07 0.01 0.01
(0.03) (0.04) (0.01) (0.02) (0.01) (0.02)
Registry
Geneva 0.74 0.76 0.61 0.65 0.41 0.48 0.01
(0.03) (0.03) (0.03) (0.03) (0.03) (0.04)
Côte d’Or 0.73 0.76 0.62 0.66 0.40 0.47
(0.02) (0.02) (0.02) (0.03) (0.03) (0.03)
Mallorca 0.70 0.72 0.53 0.56 0.29 0.35
(0.02) (0.02) (0.02) (0.03) (0.02) (0.03)
aMaximum likelihood ratio test comparing relative survival rates. bSurvival rates were not calculated for stage IV resected and stage unknown because of
insufficient number.clarifying its possible origins. Differences in both stage at diag-
nosis and treatment access and quality have been put forward in
Eurocare studies (Sant et al, 1995; Gatta et al, 1996). In our study,
it is the important difference of stage at diagnosis which mainly
explains survival inequalities. Patients in the MCR, less often
diagnosed in stage I, have a worse survival than patients in the
other two registries. After controlling for stage, survival difference
is no longer significant.
Our study provides evidence for the main role of diagnostic
conditions in survival inequalities. Up until now, there was no
organized screening programme in the three areas. In the GCR,
29% of the patients were diagnosed in stage I. This could be due to
both a better education of patients and a better access to early
endoscopy in this high standard of living urban area. On the other
hand, no variation in therapy efficiency seemed to be involved.
There was no significant difference between the registries
concerning surgical resection frequency. The reduction of survival
difference after adjusting on stage argues in favour of the absence
of important variations in treatment outcomes between the three
areas. In our study, stage-specific survival rates were lower than
the ones observed among patients treated by optimized surgical
procedures in specialized centres (MacFarlane et al, 1993;
Arbman et al, 1996). Series collected by cancer registries have the
major advantage of collecting all the cases diagnosed in a well-
defined population, avoiding the selection bias of hospital-based
series. Variations of treatment outcomes depending on surgical
skills and hospital performances are very plausible within each of
the three areas as reported in other populations (McArdle et al,
1991; Holm et al, 1997; Simons et al, 1997).
In international survival comparisons, bias may be caused by
several methodological problems (Berrino et al, 1995) and compa-
rability of data in each population needs to be investigated. This
was performed in a preliminary work (Monnet et al, 1998), which
showed the high completeness and validity of rectal cancer data in
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Table 3 Five-year crude and relative survival rates by stage in the three registries
Five-year survival rates (s.d.)
Geneva Côte d’Or Mallorca
Crude Relative Crude Relative Crude Relative
Stagea
I (T1–T2 N0 M0) 0.75 0.87 0.68 0.80 0.60 0.68
(0.06) (0.06) (0.05) (0.06) (0.06) (0.08)
II (T3–T4 N0 M0) 0.57 0.67 0.57 0.68 0.46 0.54
(0.07) (0.08) (0.05) (0.06) (0.05) (0.06)
III (N1–N2 M0) 0.26 0.29 0.25 0.29 0.23 0.27
(0.07) (0.08) (0.05) (0.05) (0.04) (0.05)
IV (M1) 0.00 0.00 0.02 0.02 0.02 0.02
(0.00) (0.00) (0.02) (0.02) (0.02) (0.02)
aSurvival rates were not calculated for stages IV resected, loco-regional (T4 Nx M0), undetermined (Tx Nx M0) and for stage
unknown because of insufficient number.
Table 4 Regression analysis of relative survival rates in rectal cancer: step-wise procedure for testing the covariate
significance
Model Regressor Deviance df P-value
1 follow-up years 870 370
2 model 1 + stage 403 365 <0.001
3 model 2 + age 399 363 >0.10
4 model 3 + sex 397 362 >0.30
5 model 4 + registry 396 360 >0.50
6 model 2 + stage follow-upa 379 363 <0.001
df, degrees of freedom. aModel adjusted by including two interaction terms: (1) first 2 years of follow-up and stages
undetermined and IV; (2) second year of follow-up and stage III.
Table 5 Relative excess death risks in rectal cancer (model 5).
Variable Relative risk 95% confidence
interval
Age (years)
<50 1
50–64 0.76 0.52–1.10
65–79 0.94 0.66–1.35
Sex
Male 1
Female 1.12 0.91–1.37
Stage
I (T1–T2 N0 M0)1
II (T3–T4 N0 M0) 1.88 1.16–3.03
III (N1–N2 M0) 5.23 3.36–8.13
Loco-regional (T4 Nx M0) 14.10 8.31–23.83
Undetermined (Tx Nx M0) 8.80 5.02–15.43
IV (M1) 25.40 16.10–40.10
Registry
Geneva 1
Côte d’Or 1.00 0.76–1.32
Mallorca 1.11 0.85–1.44the three registries for patients up to 79 years. Therefore no issue
of patient selection, definition of the disease, follow-up system or
method of calculating survival duration may explain our results.
In this population study, as in other published series, stage at
diagnosis was the major prognostic factor. Stage-specific survival
rate and relative risk estimates were close to those reported in
other populations (Kune et al, 1990; Arbman et al, 1995; Roncucci
et al, 1996). Relative risks, as shown in Table 4, have to be consid-
ered as average estimates since the hazards were non-proportional
across stage classes for the 5 years of follow-up. In advanced
stages, the excess death risks were maximum for the first 2 years
and decreased thereafter, while the excess death risk of stage III
patients was more marked for the second year. The classification
used in our study was consistent with TNM staging, based on
histological examinations and took into account the primary treat-
ment received by patients. In colorectal cancers, staging and
surgical treatment are interrelated procedures (Kronborg, 1993).
Our classification was stratified with surgical treatment modalities
in order to reduce the differences in stage measure conditions
between the registries. Indeed, as they depend on diagnostic tech-
nology and medical practice, stage measure conditions vary with
time and place (Feinstein et al, 1985). The slightly higher
frequency of metastases in the GCR could be due to a more thor-
ough exploration of patients in the Geneva canton. As pointed out
by several authors (Blenkinsopp et al, 1981; Bull et al, 1997) the
quality of routine pathology data noticeably varies between labora-
tories. It depends in particular on the thoroughness of the examina-
tion and on the completeness of lymph node resection. These
criteria could not be analysed in our study and we assume the data
were of similar quality, on average, in the three areas. Our results
cannot be explained by an information bias since there is a survival
difference between the registries in univariate analysis.
The poorer prognosis in young patients, when compared with
older ones, is still debated (Smith et al, 1989; Isbister et al, 1990;
Enblad et al, 1990). In our study, after controlling for stage,
patients under 50 tended to have a lower survival than older
patients, but the difference did not become significant. Moreover,
poor prognosis stages were more frequent among patients under
50 than among older ones: before 50 years, 33% of patients were
diagnosed with lymph node metastases and 23% with visceral
metastases versus, respectively, 22% and 17% of patients aged
50 years and over (P = 0.02).
Results from population-based studies reveal that rectal cancer
prognosis is highly correlated to the health service ability to
provide all patients with both an early diagnosis and treatment in
specialized centres. By studying the effect of tumour stage at diag-
nosis, our work highlights the importance of access to diagnostic
examinations. A delay in diagnosis, particularly among younger
patients, leads to more advanced and less curable tumours. The
determinants of access to diagnosis are numerous and complex.
They include endoscopy availability and financing, practitioner
education as well as population information. Further studies are
required to investigate the role of health care supply and organiza-
tion and to compare practice standards.
Rectal cancer outcomes in leading populations, such as the
canton of Geneva, could be considered as an attainable objective
by public health authorities in less advanced countries. Current
differences between European populations suggest that health
benefits within health policies’ reach could be greater in many
countries than that of any of the adjuvant therapies currently under
study.
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